Form PTO-14	-	partment of Commerce and Trademark Office	Attorney Docket 2003946-0110 (ANDI/US)	In re App 10/507,0	olication No. 67		
NOV 1 0 20C4	INFORMATIO	INFORMATION		Applicant: Boivin et al			
Use several sheets if necessary) U.S. PATENT DOCUMENTS			Filing Date: Group: September 8, 2004 NYA				
U.S. PATENT	DOCUMENTS		30,000				
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass		
Initials							
/SY/	† 5,674,892	Giese, et al.	October 7, 1997	514	450		
	+ 5,727,726	Giese, et al	March 17, 1998	514	449		
/SY/	† 5,795,910	Giese, et al.	August 18, 1998	514	450		
/SY/	† 6,265,603 B1	Lewis, et al.	July 24, 2001	560	9		
U.S. PATENT	APPLICATIONS						
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:		
/SY/	†10/657,910	Chiba, et al.	September 9, 2003		1614		
FOREIGN PA	TENT DOCUMENTS	}					
Examiner's Initials	Document No.	Country	International Publication Date	Translation			
				Yes	No		
/SY/	EP 0 606 044 A1	EP	November 29, 1993				
/SY/	GB 2 323 845 A	UK	October 7, 1998				
/SY/	JP 8- 40893	JP	February 13, 1996		X		
/SY/	WO 96/13259	PCT	May 9, 1996				
/SY/	WO 00/38674	PCT	July 6, 2000				
/SY/	WO 00/39314	PCT	July 6, 2000				
·/SY/	WO 01/36003 A2	PCT	May 25, 2001				
/SY/	WO 02/48136 A1	PCT	June 20, 2002		X		
OTHER DOC	CUMENTS						
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)						
/SY/	Copy of Internationa	Copy of International Search Report for PCT/US03/07377.					
/SY/	Agatsuma, et al., "Revised Structure and Stereochemistry of Hypothemycin", Chem. Pharm. Bull.; 41(2): 373-375 1993.						
/SY/	Chen, et al., "Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes", Oncogene, 18: 7649-7476, 1999.						
/SY/	Dombrowski, et al., "Production of a Family of Kinase-inhibiting Lactones from Fungal Fermentations", J. Antibiot., 52(12): 1077-1085, 1999.						

U.S.S.N. 10/507,067 3742740_1.DOC

Form PTO-1449	U.S. Department of Commerce	Attorney Docket	In re Application No.			
(REV. 8-03)	Patent and Trademark Office	2003946-0110	10/507,067			
		(ANDI/US)				
INFORMATION		Applicant: Boivin et al				
	DISCLOSURE STATEMENT	Filing Date:	Group:			
((Use several sheets if necessary)	September 8, 2004	NYA			
/SY/	Ellestad, et al., "New Zearalenone Related Macrolides and Isocoumarins from an Unidentified Fungus", J. Org. Chem., 43(12):2339-2343, 1978.					
/SY/	Li, et al., "Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination", <i>The FASEB Journal</i> , Article 10.1096/fj.01-0172fje, published online September 17, 2001.					
/SY/	Kastelic, et al., "Induction of Rapid IL=1β mRNA Degradation in THP-1 Cells Mediated Through the AU-Rich Region in the 3'UTR by a Radicocol Analogue", Cytokine 8(10): 751-761, 1996.					
. /SY/	Matsuoka, et al., "Inhibition of HgCl ₂ -induced mitogen-activated protein kinase activation by LL-Z1640-2 in CCRF-CEM cells", Eur. J. Pharmacol., 409(2): 155-158, 2000.					
/SY/	Rawlins, et al., "Inhibition of endotoxin-induced TNF-α production in macrophages by 5Z-7-oxo-zeaenol and other fungal resorcylic acid lactones", <i>Int. J. Immunopharmacol.</i> , 21(12): 799-814, 1999.					
- /SY/	Tak, et al., "NF-κB-a key role in inflammatory diseases", J. Clin. Investigation, 107(1): 7-11, 2001.					
; /SY/	Takehana, et al., "A radicicol-Related Macrocyclic Nonaketide Compound, Antibiotic LL-Z1640-2, Inhibits the JNK/p38 Pathways in Signal-Specific Manner", Biochem. Biophys. Res. Commun., 257(1): 19-23, 1999.					
ISYI	Tatsuta, et al., "The First Total Synthesis of a Macrocyclic Anti-protozoan, LL-Z1640-2", Chem. Lett., Vol. 2, 172-173, 2001.					
ISYI	Yamamoto, et al., "Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer", J. Clin. Investigation, 107(2), 135-142, 2001.					
	-					
			•			
		***	Augus			
	(O)	DAME CONCERNO	OFF 07/22/2007			
EXAMINER: I	/Shawquia Young/ nitial if citation considered, whether or not citation	DATE CONSIDER				

† Copies of references not included – requirement waived pursuant to USPTO OG Notice of 8/5/03

through citation if not in conformance and not considered. Include copy of this form with next communication to

U.S.S.N. 10/507,067 2 of 2 3742740_1.DOC

applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office SUPPLEMENTAL DEFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Atty. Docket: 2003946-0110 (ANDI/US) Applicant: Boivin, et al. Filing Date: September 8, 2004	In re Application No. 10/507,067 Group: Not yet assigned			
U.S. PATENT D Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass		
Initials	C.D. I mont 110.		•				
U.S. PATENT A	PPLICATIONS				1		
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:		
	and the second s						
FOREIGN PATENT DOCUMENTS							
Examiner's	Document No.	Country	Date	Translation			
Initials				Yes	No		
/SY/ 1.	WO03/076424A1	PCT	September 18, 2003				
OTHER DOCU	MENTS				e the second		
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)						
EXAMINER	DATE CONSIDERED /Shawquia Young/ 07/23/2007						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							